OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
222556

Jinhai Medical Technology Ltd

Employment ServicesVerified

Jinhai Medical Technology Ltd has a liquidity position that is characterized by a current ratio of 1.84, indicating that it has 1.84 times more current assets than current liabilities. However, the company's operating cash flow is negative at -5.57 million SGD, and its free cash flow is also negative at -15.65 million SGD, suggesting that it is not generating sufficient cash from operations to fund its activities. The company's debt-to-equity ratio is 0.29, which is relatively low, but the negative net cash position after subtracting total debt is a key liquidity flag. In terms of profitability, Jinhai Medical Technology Ltd is currently unprofitable, with a net income of -1.71 million SGD and an operating income of -16.49 million SGD. The company's return on equity is -0.333, and its return on assets is -0.1923, both of which are significantly below the industry median for employment services. These metrics indicate that the company is not effectively utilizing its equity or assets to generate returns. The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification reported. This lack of diversification could expose the company to higher risk if demand in its primary market declines. Looking at the company's growth trajectory, there is no specific outlook provided for the current or next fiscal year. However, the company's negative operating and net income suggest that it is not currently experiencing growth and may be facing operational challenges. The company's capital expenditure is minimal at -0.095 million SGD, indicating that it is not investing heavily in new projects or expansion. The risk assessment for Jinhai Medical Technology Ltd indicates a medium level of liquidity risk, with a key flag being the negative net cash position after subtracting total debt. The company's dilution risk is assessed as low, and there are no specific dilution sources identified in the provided data. The company's financial performance and liquidity position suggest that it may need to seek additional financing, which could lead to dilution in the future. Recent events and filings do not provide specific details about the company's operations or financial performance beyond what is disclosed in the financial snapshot. The company's financial statements indicate ongoing operational losses and negative cash flows, which may be a concern for investors.

30-day price · 2225+1.27 (+57.7%)
Low$2.10High$5.15Close$3.47As of18 May, 00:00 UTC
Profile
CompanyJinhai Medical Technology Ltd
Ticker2225.HK
SectorIndustrials
BusinessIndustrial & Commercial Services
Industry groupIndustrial & Commercial Services
IndustryEmployment Services
AI analysis

Business. Jinhai Medical Technology Ltd provides employment services, primarily operating in the industrial and commercial services sector.

Classification. The company is classified under the Employment Services industry within the Industrial & Commercial Services business sector, with a confidence level of 0.92.

Jinhai Medical Technology Ltd has a liquidity position that is characterized by a current ratio of 1.84, indicating that it has 1.84 times more current assets than current liabilities. However, the company's operating cash flow is negative at -5.57 million SGD, and its free cash flow is also negative at -15.65 million SGD, suggesting that it is not generating sufficient cash from operations to fund its activities. The company's debt-to-equity ratio is 0.29, which is relatively low, but the negative net cash position after subtracting total debt is a key liquidity flag. In terms of profitability, Jinhai Medical Technology Ltd is currently unprofitable, with a net income of -1.71 million SGD and an operating income of -16.49 million SGD. The company's return on equity is -0.333, and its return on assets is -0.1923, both of which are significantly below the industry median for employment services. These metrics indicate that the company is not effectively utilizing its equity or assets to generate returns. The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification reported. This lack of diversification could expose the company to higher risk if demand in its primary market declines. Looking at the company's growth trajectory, there is no specific outlook provided for the current or next fiscal year. However, the company's negative operating and net income suggest that it is not currently experiencing growth and may be facing operational challenges. The company's capital expenditure is minimal at -0.095 million SGD, indicating that it is not investing heavily in new projects or expansion. The risk assessment for Jinhai Medical Technology Ltd indicates a medium level of liquidity risk, with a key flag being the negative net cash position after subtracting total debt. The company's dilution risk is assessed as low, and there are no specific dilution sources identified in the provided data. The company's financial performance and liquidity position suggest that it may need to seek additional financing, which could lead to dilution in the future. Recent events and filings do not provide specific details about the company's operations or financial performance beyond what is disclosed in the financial snapshot. The company's financial statements indicate ongoing operational losses and negative cash flows, which may be a concern for investors.
Key takeaways
  • Jinhai Medical Technology Ltd is currently unprofitable with negative operating and net income.
  • The company's liquidity position is weak, with negative operating and free cash flows.
  • The company's return on equity and return on assets are significantly below the industry median.
  • The company's revenue is concentrated in a single segment, with no significant geographic diversification.
  • The company's capital expenditure is minimal, indicating limited investment in growth.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencySGD
Revenue$46.3M
Gross profit$7.2M
Operating income-$16.5M
Net income-$17.1M
R&D
SG&A
D&A
SBC
Operating cash flow-$5.6M
CapEx-$95.0k
Free cash flow-$15.6M
Total assets$88.8M
Total liabilities$37.5M
Total equity$51.3M
Cash & equivalents
Long-term debt$14.9M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$46.3M-$16.5M-$17.1M-$15.6M
FY-1$50.2M-$17.5M-$18.0M-$17.7M
FY-2$45.6M-$3.0M-$3.1M-$4.2M
FY-3$22.3M$869.3k$468.1k$321.2k
FY-4$21.9M$70.0k-$246.2k$1.3M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$88.8M$51.3M
FY-1$58.9M$31.8M
FY-2$62.2M$37.5M
FY-3$40.3M$24.4M$15.4M
FY-4$33.8M$24.3M$16.3M
PeriodOCFCapExFCFSBC
FY0-$5.6M-$95.0k-$15.6M
FY-1-$3.3M-$1.0M-$17.7M
FY-2-$1.9M-$1.2M-$4.2M
FY-3$4.2M-$1.2M$321.2k
FY-4$3.3M-$607.1k$1.3M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$51.3M
Net cash-$14.9M
Current ratio1.8
Debt/Equity0.3
ROA-19.2%
ROE-33.3%
Cash conversion33.0%
CapEx/Revenue-0.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Employment Services · cohort 1 companies
Metric2225Activity
Op margin-35.6%1.4% medp25 1.4% · p75 1.4%bottom quartile
Net margin-36.9%2.3% medp25 0.3% · p75 7.7%bottom quartile
Gross margin15.5%37.2% medp25 37.2% · p75 37.2%bottom quartile
CapEx / revenue-0.2%3.0% medp25 3.0% · p75 3.0%bottom quartile
Debt / equity29.0%21.3% medp25 4.4% · p75 42.4%above median
Source: analysis-pipeline (hybrid)Generated: 2026-05-19 00:26 UTCJob: a4722b16